Samsara Biocapital
Investor profile
Venture capital
Samsara Biocapital has backed 3 European tech companies across 4 funding rounds between 2021 and 2023, joining rounds totalling €281M. Most active in Healthtech. Data as of Nov 2026.
Deals
4
distinct rounds
Companies
3
backed
Active span
2021–2023
3 yrs
Total round €
€281M
sum of rounds joined
Deals by year
distinct rounds / yearSamsara Biocapital — deals by year — interactive chart.
Data table
| Samsara Biocapital — deals by year | |
|---|---|
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
Top sectors
by dealsSamsara Biocapital — top sectors — interactive chart.
Data table
| Samsara Biocapital — top sectors | |
|---|---|
| Healthtech | 4 |
Stages
by dealsSamsara Biocapital — stages — interactive chart.
Data table
| Samsara Biocapital — stages | |
|---|---|
| Series A | 2 |
| Other | 1 |
| Series B | 1 |
Countries
by dealsSamsara Biocapital — countries — interactive chart.
Data table
| Samsara Biocapital — countries | |
|---|---|
| UK | 3 |
| Switzerland | 1 |
Co-investment network
shared roundsCo-investment network — interactive chart.
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
Frequent co-investors
shared rounds- Jeito Capital2
- MRL Ventures Fund2
- SV Health Investors2
- Adage Capital Management1
- Bain Capital Life Sciences1
- BioMedPartners1
- CureDuchenne Ventures1
- Deerfield1
- Fiscus Financial1
- GIMV1
- GL Capital1
- Gray’s Creek Capital Partners1
- Laurion Capital Management1
- Lightspeed Venture Partners1
- Mission BioCapital1
- Omega Funds1
- Oxford Sciences Innovation1
- Peak6 Strategic Capital1
- Pfizer Ventures1
- RA Capital Management1
- Schroder Adveq1
- Tudor Investment Corporation1
- Vertex Ventures1
- Viking Global Investors1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| EyeBiotech | UK | 2 | €118M |
| Pepgen | UK | 1 | €95M |
| Immunos Therapeutics | Switzerland | 1 | €68M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Pepgen | Other | €95M | 2021-08 |
| Immunos Therapeutics | Series B | €68M | 2022-06 |
| EyeBiotech | Series A | €61M | 2023-11 |
| EyeBiotech | Series A | €57M | 2022-02 |